Madrid, Spain, 13 June 2013: Study findings first presented today at EULAR 2013, the Annual Congress of the European League Against Rheumatism, demonstrate the efficacy of canakinumab at tapering corticosteroid (CS) use in patients with SJIA.
Successful CS tapering was achieved within 20 weeks in almost half of patients (44.5%, p<0.0001); at the end of the tapering phase, the CS-free patients had active arthritis in fewer joints, a lower physician's global assessment of disease activity and a less limited range of motion.